Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD

Tema Etfs LLC grew its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 34.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 126,921 shares of the company’s stock after purchasing an additional 32,694 shares during the period. Tema Etfs LLC owned about 0.07% of Revolution Medicines worth $5,927,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nextech Invest Ltd. increased its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Bellevue Group AG raised its position in shares of Revolution Medicines by 4.7% in the second quarter. Bellevue Group AG now owns 4,579,300 shares of the company’s stock worth $168,472,000 after buying an additional 205,000 shares in the last quarter. Norges Bank bought a new position in shares of Revolution Medicines in the second quarter worth approximately $62,584,000. Westfield Capital Management Co. LP lifted its position in Revolution Medicines by 55.0% during the second quarter. Westfield Capital Management Co. LP now owns 1,649,404 shares of the company’s stock valued at $60,682,000 after purchasing an additional 585,358 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new position in Revolution Medicines in the second quarter worth $44,148,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Raymond James Financial increased their target price on shares of Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a report on Friday, October 17th. Royal Bank Of Canada began coverage on shares of Revolution Medicines in a report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price objective for the company. National Bankshares set a $80.00 price target on Revolution Medicines in a research report on Friday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, UBS Group raised Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $78.94.

Revolution Medicines Stock Up 10.5%

Shares of NASDAQ:RVMD opened at $118.64 on Monday. The company has a market cap of $22.94 billion, a price-to-earnings ratio of -22.95 and a beta of 0.99. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $121.62. The company has a 50-day moving average price of $76.36 and a 200 day moving average price of $54.18. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period in the prior year, the firm earned ($0.94) EPS. As a group, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Reports that Merck is in talks to acquire Revolution Medicines for roughly $30–32 billion, a direct M&A bid narrative that can justify a sizable takeover premium and is the primary driver of today’s rally. Merck in talks (WSJ)
• Positive Sentiment: Takeover buzz broadened as media reported additional suitors and renewed buyout interest (markets often bid target stocks higher on competing-acquirer speculation). Takeover buzz, another suitor emerges (Barron’s)
• Positive Sentiment: FDA granted Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutant NSCLC — a substantive clinical/regulatory win that strengthens RVMD’s strategic value to acquirers and supports a higher acquisition valuation. Breakthrough Therapy Designation (GlobeNewswire)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates aggressive bullish/speculative positioning by traders ahead of or on takeover rumors, amplifying short-term upside momentum. (market reports)
• Neutral Sentiment: The stock experienced a temporary LULD (limit up/limit down) pause during trading, a procedural volatility-control measure that often accompanies sudden price moves but does not change fundamentals.
• Negative Sentiment: Earlier takeover reports referenced AbbVie interest but AbbVie publicly denied talks, which previously triggered volatility and a pullback — a reminder that rumor-driven moves can reverse if potential bidders decline to engage. AbbVie denies talks (Barron’s)
• Negative Sentiment: Revolution remains a loss-making biotech (recent quarterly EPS missed estimates), so absent a takeover premium the stock’s valuation relies on successful late-stage clinical outcomes and eventual commercialization. (company filings/earnings)

Insider Buying and Selling

In related news, CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total transaction of $980,000.00. Following the completion of the transaction, the chief financial officer owned 108,065 shares in the company, valued at $10,590,370. The trade was a 8.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Stephen Michael Kelsey sold 5,447 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total value of $418,438.54. Following the completion of the sale, the insider directly owned 278,600 shares of the company’s stock, valued at approximately $21,402,052. This represents a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 243,792 shares of company stock worth $19,757,740 in the last three months. 8.20% of the stock is owned by company insiders.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.